Chaillon A, et al. - Despite new AASLD/IDSA guidelines that recommend hepatitis C virus (HCV) screening in pregnant women, the Society of Maternal-Fetal Medicine and the CDC do not recommend screening this group. Therefore, researchers evaluated the cost-effectiveness of HCV screening for pregnant women in the United States. Using an HCV natural history Markov model, they evaluated the cost-effectiveness of universal HCV screening of pregnant women followed by treatment after pregnancy compared with background risk-based screening from a healthcare payer perspective. According to findings, universal antenatal screening was cost effective in all treatment eligibility scenarios (mean incremental cost-effectiveness ratio < $3,000/ quality-adjusted life years gained) and should be recommended nationally.